Abstract
Introduction Gastrointestinal tract is the most common site of extra nodal non-Hodgkin’s lymphoma (EN-NHL). Most of the published data have been on gastric NHL with limited studies on primary intestinal - Non-Hodgkin’s Lymphoma (PI-NHL) considering rare incidence. We performed epidemiological and survival analysis for PI-NHL from the Surveillance, Epidemiology, and End Results (SEER) 18 database.
Methods A total of 9143 PI-NHL cases of age ≥18 years were identified from the SEER 18 database for the period 2000-2015. 8568 Patients were included for survival analysis. Cause specific Survival (CSS) and overall survival analysis (OS) were done for PINHL and PI-diffuse large B-cell lymphoma (PI-DLBCL) using gender, age of onset, treatment, histology, stage, and Year of diagnosis. Survival analysis was done by using cox-proportional hazard model and Kaplan Meier plot with log-rank test.
Results The percentage of PI-NHL of all the intestinal cancers and extra nodal non-Hodgkin’s lymphoma were 1.35 %, and 10.52%, respectively. The age-adjusted incidence was 0.9145/100,000 population for the study population. PI-NHL was more common among patients aged≥60 Years, male and non-Hispanics whites. Majority of patients were diagnosed at stage 1 and 2 (74%), and DLBCL (44.8%) was the most common histology. In OS analysis, Significant increased risk of mortality was seen with T-cell NHLs vs. DLBCL (HR – 2.56), patients aged ≥60 vs <60 Years (HR – 2.87), stage 4 vs Stage 1 (HR – 1.93), male vs. female (HR- 1.17), with best outcome seen in patient treated with combination of chemotherapy and surgery vs. none (HR – 0.45). Similar results were seen in CSS and for primary intestinal DLBCL as well. Significant improvement in outcomes was observed for PI-DLBCL patients receiving chemotherapy with/without surgery.
Conclusion Findings from our large, population-based study reveal PI-NHL is a rare type of intestinal malignancy with significant difference in survival based on histological and epidemiological characteristics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Deidentified patient data were collected from Surveillance, Epidemiology, and End results Database under data user agreement with National Cancer Institute. Ethical review and approval were waived for this study, due to the de-identified information of the patients included in the public Surveillance, Epidemiology, and End Results database.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
